Market Overview

A Contrarian Call: Compass Point Upgrades Banking Regulator Magnet Ocwen Financial

A Contrarian Call: Compass Point Upgrades Banking Regulator Magnet Ocwen Financial

Fred Small of Compass Point Research believes Ocwen Financial Corp (NYSE: OCN)'s 54-percent plunge on Thursday created a buying opportunity. The analyst upgraded shares of Ocwen from Neutral to Buy but with a price target lowered from $5 to $3.50 for three main reasons.

1. 'Mispriced' Regulatory Risk

According to Small, the regulatory risk is "mispriced" following the "blizzard" of lawsuits and cease-and-desist orders from more than 20 states. As such, the probability of Thursday's "drama" creating ongoing concerns for Ocwen is low. In addition, the $1.5 billion estimate of Ocwen's escrow reconciliation and restitution isn't a real contingent liability.

2. New Residential Investment

Second, the analyst believes New Residential Investment Corp (NYSE: NRZ) is unlikely to transfer the majority of Ocwen's sub-servicing to another servicer because there are several risks involved in doing so.

3. Good Riddance To MSRs

Finally, Small suggested there is now a "complete deflation of recent optimism" surrounding Ocwen's ability to begin acquiring MSRs (mortgage servicing rights) in the near term. To this, the analyst simply states, "good riddance" as optimism about any future MSR purchases is no longer priced in to the stock and regulatory risk is also "over-baked."

Related Links:

Ocwen Shares Pinned Down, Tag-Teamed By Federal And State Regulators

7 Biggest Price Target Changes For Friday

Latest Ratings for NRZ

Sep 2019Initiates Coverage OnBuy
Mar 2019Initiates Coverage OnBuy
Oct 2018Initiates Coverage OnOutperform

View More Analyst Ratings for NRZ
View the Latest Analyst Ratings

Posted-In: Compass Point ResearchAnalyst Color Long Ideas News Upgrades Analyst Ratings Movers Trading Ideas Best of Benzinga


Related Articles (OCN + NRZ)

View Comments and Join the Discussion!

Mid-Day Market Update: CAI International Gains On Strong Results; Adamis Pharmaceuticals Shares Slide

Microsoft Pledges Not To Miss Out On The Next Big Tech Product